Mesenchymal stem cell therapy for ischemic stroke: Novel insight into the crosstalk with immune cells

Tan, Nana; Xin, Wenqiang; Huang, Min; Mao, Yuling

doi:10.3389/fneur.2022.1048113

Cited by 11 publications

(4 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar capacity is also replicated for CD4 and CD8 positive cells, as well as for dendritic cells. The effect on the B cells resulted in an increase in IL-10 production [22].…”

Section: Stroke: Description Outcomes and Possible Therapiesmentioning

confidence: 98%

State of the Art and Future of Stem Cell Therapy in Ischemic Stroke: Why Don’t We Focus on Their Administration?

Valeri

Mazzon

2023

Bioengineering

View full text Add to dashboard Cite

Stroke is one of the leading causes of death and disability worldwide, so there is an urgent need to find a therapy for the tragic outcomes of this cerebrovascular disease. Stem cells appeared to be a good solution for many conditions, so different experiments were made to establish stem cells as a feasible therapy for stroke. The aim of this review is to analyze the state of the art of stem cell therapy for stroke and if the route of administration could represent a valid adjusting point for ameliorating the therapy’s outcome. To obtain this, we searched the scientific literature of the last 10 years for relevant in vitro and in vivo evidence regarding stem cells’ potential in stroke therapy. In vitro evidence points to hypoxia, among the preconditioning strategies, as the most used and probably efficient method to enhance cells qualities, while in vivo results raise the question if it is the type of cells or how they are administrated which can make the difference in terms of efficiency. Unfortunately, despite the number of clinical trials, only a few were successfully concluded, demonstrating how urgent the necessity is to translate pre-clinical results into clinics. Since any type of stem cell seems suitable for therapy, the chosen route of administration corresponds to different engraftment rates, distribution and efficiency in terms of the beneficial effects of stem cells. Intravenous administration was widely used for delivering stem cells into the human body, but recently intranasal administration has given promising results in vivo. It allows stem cells to efficiently reach the brain that was precluded to intravenous administration, so it is worth further investigation.

show abstract

“…A similar capacity is also replicated for CD4 and CD8 positive cells, as well as for dendritic cells. The effect on the B cells resulted in an increase in IL-10 production [22].…”

Section: Stroke: Description Outcomes and Possible Therapiesmentioning

confidence: 98%

State of the Art and Future of Stem Cell Therapy in Ischemic Stroke: Why Don’t We Focus on Their Administration?

Valeri

Mazzon

2023

Bioengineering

View full text Add to dashboard Cite

show abstract

“…MSCs have been found to stimulate angiogenesis [ 133 ], stabilize the blood–brain barrier [ 134 ], and modulate the immune system [ 135 ]. In several animal models of subacute, acute, or chronic ischemic stroke, MSC transplantation has demonstrated therapeutic effects, with encouraging results even in small clinical studies [ 136 , 137 ].…”

Section: Applications Of Plga-based Nanostructures In Cell Transplant...mentioning

confidence: 99%

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

Yan,

Huang,

Feng

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

With the accelerated development of nanotechnology in recent years, nanomaterials have become increasingly prevalent in the medical field. The poly (lactic acid–glycolic acid) copolymer (PLGA) is one of the most commonly used biodegradable polymers. It is biocompatible and can be fabricated into various nanostructures, depending on requirements. Ischemic stroke is a common, disabling, and fatal illness that burdens society. There is a need for further improvement in the diagnosis and treatment of this disease. PLGA-based nanostructures can facilitate therapeutic compounds’ passage through the physicochemical barrier. They further provide both sustained and controlled release of therapeutic compounds when loaded with drugs for the treatment of ischemic stroke. The clinical significance and potential of PLGA-based nanostructures can also be seen in their applications in cell transplantation and imaging diagnostics of ischemic stroke. This paper summarizes the synthesis and properties of PLGA and reviews in detail the recent applications of PLGA-based nanostructures for drug delivery, disease therapy, cell transplantation, and the imaging diagnosis of ischemic stroke.

show abstract

“…Previous preclinical and clinical studies by multiple research groups, including our lab, showed that transplantation of bone marrow-mesenchymal stem cells (BM-MSCs) after stroke improves neurological recovery by modulating inflammation, promoting cell survival, and enhancing angiogenesis (9)(10)(11)(12)(13). Many of these improvements are presumably due to paracrine factors packaged in extracellular vesicles (EVs) and released by BM-MSCs as a response to stroke (13)(14)(15). BM-MSC-derived EVs contain proteins, lipids, and nucleic acids essential for cell communication that might stimulate endogenous repair processes (14).…”

Section: Introductionmentioning

confidence: 99%

Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires handling associated with repeated behavioral testing

Gomez-Galvez,

Gupta,

Kaur

et al. 2024

Preprint

View full text Add to dashboard Cite

Rehabilitation is the only current intervention that improves sensorimotor function in ischemic stroke patients, similar to task-specific intensive training in animal models of stroke. Bone marrow mesenchymal stem cells (BM-MSCs)-derived extracellular vesicles (EVs) are promising in restoring brain damage and function in stroke models. Additionally, the non-invasive intranasal route allows EVs to reach the brain and target specific ischemic regions. Yet unclear is how handling might enhance recovery or influence other therapies such as EVs after stroke. We used the transient middle cerebral artery occlusion (MCAO) model of stroke in rats to assess how intensive handling alone, in the form of sensorimotor behavioral tests, or in combination with an intranasal multidose or single dose of EVs restored neurological function and ischemic damage. Handled rats were exposed to a battery of sensorimotor tests, including the modified Neurological Severity Score (mNSS), beam balance, corner, grid walking, forelimb placement, and cylinder tests, together with Magnetic Resonance Imaging (MRI) at 2, 7, 14, 21, and 28 days post-stroke (dps). Handled MCAO rats were also exposed to an intranasal multidose of EVs (8 doses in total across four weeks, each dose containing 0.8 × 109EVs in 120 µl) or a single dose of EVs (2.4 × 109EVs in 200 µl) at 2 dps. Non-handled rats were evaluated only by mNSS and MRI at 2, 28, and 56 dps and were treated with a single intranasal dose of EVs. Our results showed that handling animals after MCAO is necessary for EVs to work and that a single cumulative dose of EVs further improves the neurological function recovered during handling without affecting ischemic damage. These results show the importance of rehabilitation in combination with other treatments and highlight how intensive behavioral testing might influence functional recovery after stroke, especially when other treatments are also given.

show abstract

Mesenchymal stem cell therapy for ischemic stroke: Novel insight into the crosstalk with immune cells

Cited by 11 publications

References 179 publications

State of the Art and Future of Stem Cell Therapy in Ischemic Stroke: Why Don’t We Focus on Their Administration?

State of the Art and Future of Stem Cell Therapy in Ischemic Stroke: Why Don’t We Focus on Their Administration?

The Recent Applications of PLGA-Based Nanostructures for Ischemic Stroke

Recovery after human bone marrow mesenchymal stem cells (hBM-MSCs)-derived extracellular vesicles (EVs) treatment in post-MCAO rats requires handling associated with repeated behavioral testing

Contact Info

Product

Resources

About